A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

The introduction of posttransplant cyclophosphamide (PTCy) made performing allogeneic hematopoietic cell transplantation (HCT) from HLA haplotype–incompatible donors possible. In a setting of PTCy and tacrolimus/mycophenolate mofetil (MMF) as a graft-versus-host disease (GVHD) prophylaxis, a periphe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Bejanyan, Nelli, Pidala, Joseph A., Wang, Xuefeng, Thapa, Ram, Nishihori, Taiga, Elmariah, Hany, Lazaryan, Aleksandr, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Faramand, Rawan, Jain, Michael D., Ochoa, Leonel, Perez, Lia Elena, Liu, Hien, Alsina, Melissa, Kharfan-Dabaja, Mohamed A., Fernandez, Hugo, Nieder, Michael L., Locke, Frederick L., Anasetti, Claudio, Ayala, Ernesto
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948297/
https://ncbi.nlm.nih.gov/pubmed/33635333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003779
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky